Favorable Effect of Short-Term Lifestyle Intervention on Human Paraoxonase-1 Activity and Adipokine Levels in Childhood Obesity

Koncsos, Péter; Serés, I.; Harangi, Mariann; Páll, Dénes; Józsa, Lajos; Bajnok, László; Nagy, Endre; Paragh, György

doi:10.1080/07315724.2011.10719976

Cited by 22 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 These discrepancies may result from the presence of separate active centers responsible for the enzyme hydrolytic activities toward paraoxon and phenyl acetate 31 as well as different reactions of these centers to molecular changes induced by oxidative stress during ME. The changes in oxidativereductive balance in response to ME were substantial enough to cause a significant increase in the antioxidant defense measured as FRAP even 30 minutes after ME.…”

Section: Discussionmentioning

confidence: 99%

Effect of exercise on plasma paraoxonase1 activity in rugby players: Dependance on training experience

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of exercise on plasma paraoxonase1 activity in rugby players: Dependance on training experience

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Important sources of variance in AREase activity that are not captured by these genotypes or the covariates of age and current smoking must account for the strong association between this activity and CAAD. Possible sources of AREase variation include rare regional variants, regional gene regulation not captured by genotyping (such as methylation), variation in genes outside the PON cluster, nongenetic factors including statin drug use [72] and diet [73, 74], as recently reviewed [75], as well as interactions among these. Evidence of interactions includes the report of the association of PON1 genotype and CHD only in subjects with diabetes [76].…”

Section: Discussionmentioning

confidence: 99%

Additional Common Polymorphisms in thePONGene Cluster Predict PON1 Activity but Not Vascular Disease

et al. 2012

View full text Add to dashboard Cite

Background. Paraoxonase 1 (PON1) enzymatic activity has been consistently predictive of cardiovascular disease, while the genotypes at the four functional polymorphisms at PON1 have not. The goal of this study was to identify additional variation at the PON gene cluster that improved prediction of PON1 activity and determine if these variants predict carotid artery disease (CAAD). Methods. We considered 1,328 males in a CAAD cohort. 51 tagging single-nucleotide polymorphisms (tag SNPs) across the PON cluster were evaluated to determine their effects on PON1 activity and CAAD status. Results. Six SNPs (four in PON1 and one each in PON2/3) predicted PON1 arylesterase (AREase) activity, in addition to the four previously known functional SNPs. In total, the 10 SNPs explained 30.1% of AREase activity, 5% of which was attributable to the six identified predictive SNPs. We replicate rs854567 prediction of 2.3% of AREase variance, the effects of rs3917510, and a PON3 haplotype that includes rs2375005. While AREase activity strongly predicted CAAD, none of the 10 SNPs predicting AREase predicted CAAD. Conclusions. This study identifies new genetic variants that predict additional PON1 AREase activity. Identification of SNPs associated with PON1 activity is required when evaluating the many phenotypes associated with genetic variation near PON1.

show abstract

“…Some studies indicate that low-calorie dietary intervention, specifically for 12 weeks, decreased the concentration of circulating ADMA in obese and overweight patients [302,303]. This effect was significant even in obese children after only a 2-week-long low-calorie dietary intervention along with exercise [304].…”

Section: Dietary Interventionmentioning

confidence: 99%

Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches

Tousoulis

Georgakis²,

Oikonomou³

et al. 2015

CMC

View full text Add to dashboard Cite

Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of nitric oxide synthase with a key role in the pathophysiology of endothelial dysfunction, in the progression of atherosclerosis and in cardiovascular diseases. Statins, renin-angiotensin-aldosterone system inhibitors, blood glucose lowering agents, insulin sensitizers, beta-blockers, estrogen replacement therapy, antioxidants, complex B vitamins, L-arginine and acetylsalicylic acid have been evaluated for their ability to reduce ADMA levels or inhibit its actions. Despite the major beneficial effects of these agents in cardiovascular disease, research has shown that their favorable actions are only partially mediated by reducing ADMA levels or by bypassing its effect in nitric oxide synthesis. Novel therapeutic approaches targeting selectively ADMA are encouraging, but have only been tested in vitro or in animal studies and further research is needed in order to conclude on how therapeutic strategies modulating ADMA actions can affect atherosclerosis progression and cardiovascular diseases.

show abstract

Favorable Effect of Short-Term Lifestyle Intervention on Human Paraoxonase-1 Activity and Adipokine Levels in Childhood Obesity

Cited by 22 publications

References 40 publications

Effect of exercise on plasma paraoxonase1 activity in rugby players: Dependance on training experience

Effect of exercise on plasma paraoxonase1 activity in rugby players: Dependance on training experience

Additional Common Polymorphisms in thePONGene Cluster Predict PON1 Activity but Not Vascular Disease

Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches

Contact Info

Product

Resources

About